Monday, March 11, 2024 12:01:07 PM
Hey stupid, those shares are not the same shares that were in the 8-K filed on March 1st... they are two separate transactions... go back and look at the first 8_k and see what the total is for that one vs the total for this one... You may have to have your mom or teacher read it to you it seems.
Here so you dont fry your tiny brain looking for it from Page 3 of the March 1 8-K notice it say locked up on the warrant exchange the 8-K from Friday was not for warrants... and it involved multiple investors not just Fife.. Here is the tricky part for you, the March 1 8-K is for a transaction that took place in 2021... The March 8th -K is for a transaction that took place in 2019... and the March 8 clearly states that this 10 million shares is for 40 shares of Series J shares... go back and look at the March 1st 8-K you will see that agreement is for different shares... The company had more then one deal with Fife
On February 27, 2024, each of the PIPE Investors entered into an exchange agreement with the Company (each, a “PIPE Warrant Exchange Agreement”
and collectively, the “PIPE Warrant Exchange Agreements”). Pursuant to the PIPE Warrant Exchange Agreements, the Company agreed to exchange the
PIPE Warrants for shares of Common Stock at an exchange ratio of 1-for-2.5 (the “PIPE Warrant Exchange Transaction”). Upon completion of the PIPE
Warrant Exchange Transaction, (i) the Company exchanged the PIPE Warrants to purchase up to 7,535,000 shares of Common Stock for 18,837,500 shares
of Common Stock (the “PIPE Exchange Shares”), and (ii) the PIPE Warrants were terminated.
Pursuant to the PIPE Warrant Exchange Agreements, the PIPE Investors agreed that, with certain exceptions, the PIPE Exchange Shares would be subject
to a twelve-month lock-up, and any other equity security of the Company (other than the PIPE Exchange Shares) owned by the PIPE Investors as of the
date of the PIPE Warrant Exchange Agreement would be subject to a six-month lock-up.
The foregoing summary of the PIPE Warrant Exchange Agreements do not purport to be complete and is subject to, and qualified in its entirety by the PIPE
Warrant Exchange Agreements, the form of which is attached as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference.
Here so you dont fry your tiny brain looking for it from Page 3 of the March 1 8-K notice it say locked up on the warrant exchange the 8-K from Friday was not for warrants... and it involved multiple investors not just Fife.. Here is the tricky part for you, the March 1 8-K is for a transaction that took place in 2021... The March 8th -K is for a transaction that took place in 2019... and the March 8 clearly states that this 10 million shares is for 40 shares of Series J shares... go back and look at the March 1st 8-K you will see that agreement is for different shares... The company had more then one deal with Fife
On February 27, 2024, each of the PIPE Investors entered into an exchange agreement with the Company (each, a “PIPE Warrant Exchange Agreement”
and collectively, the “PIPE Warrant Exchange Agreements”). Pursuant to the PIPE Warrant Exchange Agreements, the Company agreed to exchange the
PIPE Warrants for shares of Common Stock at an exchange ratio of 1-for-2.5 (the “PIPE Warrant Exchange Transaction”). Upon completion of the PIPE
Warrant Exchange Transaction, (i) the Company exchanged the PIPE Warrants to purchase up to 7,535,000 shares of Common Stock for 18,837,500 shares
of Common Stock (the “PIPE Exchange Shares”), and (ii) the PIPE Warrants were terminated.
Pursuant to the PIPE Warrant Exchange Agreements, the PIPE Investors agreed that, with certain exceptions, the PIPE Exchange Shares would be subject
to a twelve-month lock-up, and any other equity security of the Company (other than the PIPE Exchange Shares) owned by the PIPE Investors as of the
date of the PIPE Warrant Exchange Agreement would be subject to a six-month lock-up.
The foregoing summary of the PIPE Warrant Exchange Agreements do not purport to be complete and is subject to, and qualified in its entirety by the PIPE
Warrant Exchange Agreements, the form of which is attached as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference.
Recent JAGX News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/29/2026 09:23:41 PM
- Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders • ACCESS Newswire • 05/28/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/27/2026 01:10:06 PM
- Jaguar Health Compliant with Nasdaq Bid Price Rule • ACCESS Newswire • 05/27/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 09:22:44 PM
- Jaguar Health Reports First Quarter 2026 Financials • ACCESS Newswire • 05/20/2026 08:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:36:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2026 08:06:56 PM
- Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference • ACCESS Newswire • 05/20/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/19/2026 09:07:21 PM
- Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer • ACCESS Newswire • 05/19/2026 01:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/18/2026 07:06:14 PM
- Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule • ACCESS Newswire • 05/08/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 06:59:08 PM
- Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) • ACCESS Newswire • 05/06/2026 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2026 12:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 09:09:41 PM
- Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 12:00:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 01:57:16 PM
- Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs • ACCESS Newswire • 04/29/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/27/2026 01:10:06 PM
- Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split • ACCESS Newswire • 04/27/2026 01:00:00 PM
- Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) • ACCESS Newswire • 04/24/2026 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/21/2026 12:22:02 PM

